MCM
OREX

Montibus Capital Management’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Montibus Capital Management’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		$3.82M Sell
62,346
-19,512
-24% -$1.32M 0.41% 88
2013
Q2 		$4.78M Buy
+81,858
New +$5.04M 0.61% 68

Other funds holding OREX

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Montibus Capital Management's OREX Position: Q3 2013 in Review

Montibus Capital Management reduced its Orexigen Therapeutics, Inc. (OREX) stake by 24% in Q3 2013, selling an estimated $1.32M and leaving 62,346 shares worth $3.82M. The position accounts for 0.41% of the portfolio, ranked #88.

Montibus Capital Management first reported a position in OREX in Q2 2013 and has held it in 2 quarters since. The position peaked at $4.78M in Q2 2013. 130 funds tracked by Wall St. Rank hold OREX as of Q3 2013.

  • Montibus Capital Management held 62,346 shares of Orexigen Therapeutics, Inc. worth $3.82M as of Q3 2013.
  • Montibus Capital Management sold 19,512 Orexigen Therapeutics, Inc. shares in Q3 2013, an estimated $1.32M.
  • Orexigen Therapeutics, Inc. made up 0.41% of Montibus Capital Management's portfolio in Q3 2013, its #88 holding.
  • Montibus Capital Management first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and has held it in 2 quarters since.
  • Montibus Capital Management's Orexigen Therapeutics, Inc. position peaked at $4.78M in Q2 2013.
  • 130 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q3 2013.

Based on Montibus Capital Management's 13F filing for Q3 2013, filed 13 Nov 2013.